vendredi 4 octobre 2019

Onco Actu du 4 octobre 2019


1. BIOLOGIE



‘Dietary’ Vulnerability Found in Cancer Cells With Mutated Spliceosomes [Johns Hopkins]











1.1 BIOLOGIE - GÉNOME



Human Reference Genome Doesn’t Capture Full Genetic Diversity [The Scientist]











2. ETIOLOGIE



In the Pancreas, Common Fungi May Drive Cancer [NY Times]










2.11 ETIOLOGIE - ALIMENTATION



Meat’s Bad for You! No, It’s Not! How Experts See Different Things in the Data [NY Times]










2.13 ETIOLOGIE - NMDA



FDA calls generic Zantac carcinogen levels 'unacceptable,' but pushes back against lab claims [Biopharma Dive]











3.1.1 PRÉVENTION - TABAC - E-CIGS



‘I really love the feeling’: As vaping injuries climb, doctors struggle to wean youth off nicotine [STAT]










U.S. vaping-related deaths rise to 18, illnesses surpass 1,000: CDC [Reuters]











New York court blocks state ban on flavored e-cigarettes [Reuters]











4.12 BIOPSIES LIQUIDES



This Oncologist Doesn’t Want Another Person to Die From a Cancer That Was Detected Too Late [Fortune]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Stanford chemist develop ‘infrared vision’ for cancer immunotherapy [Stanford]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients [Genome Web]











Breast cancer: Call for genetic screening for all [BBC News]











A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer [JAMA Oncology]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Boxing move knocks cancer cells out [Netherlands Cancer Institute]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Adicet Bio reels in $80M to push lymphoma program into the clinic [Fierce Biotech]











ARC-T? Alternative CAR-T startup bags $85M for clinical quest to redirect 'blind hunter' T cells [EndPoints]











Neoantigen player PACT Pharma woos Tim Moore from Kite to run technical ops [EndPoints]











5.12.7 IMMUNOTHÉRAPIES - VACCINS



Discovery may expand cancer vaccine capabilities [Arizona State University]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Immunotherapy for triple negative breast cancer gets initial ‘no’ for NHS in England [Cancer Research UK]











5.2 PHARMA



FDA Grants Breakthrough Therapy Designation to Cobimetinib for MEK Inhibition in Histiocytic Neoplasms, Research Led by MSK [Memorial Slaon Kettering Cancer Center]











Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer [Janssen]











5.2.3 PHARMA - ÉCONOMIE



After failed cancer test, Tocagen slashes staff [Fierce Biotech]











Pivotal failure triggers job cuts at San Diego-based Tocagen [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



When can RWE translate into credible evidence? EMA officials discuss [EndPoints]










6.1 OBSERVATION



Breast cancer deaths almost halved since 1989, UK figures show [The Guardian]











Head and neck melanomas increasing, especially among boys and young men [Reuters]











Record numbers beating breast cancer in the UK [Cancer Research UK]











6.10.1 POLITIQUES (USA)



Trump 'wouldn't be surprised' if pharma was behind impeachment inquiry [Fierce Pharma]











6.6 PUBLICATIONS



A kinder research culture is possible [Nature]











6.7.1 IA/BIOINFORMATIQUE



ICR forms collaboration with AI drug discovery company to develop new possible treatments in rare childhood cancer DIPG [Institute of Cancer Research]











6.7.3 DMP



Data standards may be wonky, but they will transform health care [STAT]